PL3484916T3 - Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania - Google Patents

Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania

Info

Publication number: PL3484916T3
Authority: PL; Poland
Prior art keywords: methods; antibodies specific; hyperphosphorylated tau; hyperphosphorylated; tau
Prior art date: 2016-07-12

Application number

PL17739940T

Other languages

English (en)

Inventor

Jan Torleif Pedersen

Kristian Kjaergaard

Lars Østergaard Pedersen

Ayodeji Abdur-Rasheed Asuni

Nina Helen Rosenqvist

Justus Claus Alfred Daechsel

Karsten Juhl

Lena TAGMOSE

Mauro Marigo

Thomas Jensen

Søren CHRISTENSEN

Laurent David

Christiane VOLBRACHT

Lone HELBO

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-12

Filing date

2017-07-07

Publication date

2021-07-19

2017-07-07 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2021-07-19 Publication of PL3484916T3 publication Critical patent/PL3484916T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Psychology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Mycology (AREA)
Heart & Thoracic Surgery (AREA)

PL17739940T 2016-07-12 2017-07-07 Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania PL3484916T3 (pl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DKPA201600416		2016-07-12
DKPA201700005		2017-01-04
DKPA201700008		2017-01-04
DKPA201700179		2017-03-14
EP17739940.9A EP3484916B1 (en)	2016-07-12	2017-07-07	Antibodies specific for hyperphosphorylated tau and methods of use thereof
PCT/EP2017/067067 WO2018011073A1 (en)	2016-07-12	2017-07-07	Antibodies specific for hyperphosphorylated tau and methods of use thereof

Publications (1)

Publication Number	Publication Date
PL3484916T3 true PL3484916T3 (pl)	2021-07-19

Family

ID=60941665

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17739940T PL3484916T3 (pl)	2016-07-12	2017-07-07	Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania

Country Status (40)

Country	Link
US (5)	US10472415B2 (pl)
EP (2)	EP3484916B1 (pl)
JP (2)	JP7029415B2 (pl)
KR (1)	KR102551971B1 (pl)
CN (2)	CN109618556B (pl)
AU (2)	AU2017295608B2 (pl)
BR (1)	BR112018004916A2 (pl)
CA (1)	CA3027561A1 (pl)
CL (1)	CL2019000082A1 (pl)
CO (1)	CO2018014325A2 (pl)
CY (1)	CY1123995T1 (pl)
DK (1)	DK3484916T3 (pl)
DO (1)	DOP2018000281A (pl)
EC (1)	ECSP19005417A (pl)
ES (1)	ES2862427T3 (pl)
GE (1)	GEP20217222B (pl)
HR (1)	HRP20210522T1 (pl)
HU (1)	HUE053679T2 (pl)
IL (1)	IL263530B2 (pl)
JO (1)	JOP20180117B1 (pl)
LT (1)	LT3484916T (pl)
MA (2)	MA56165A (pl)
MX (1)	MX2019000476A (pl)
MY (1)	MY197836A (pl)
NI (1)	NI201900003A (pl)
NZ (1)	NZ748983A (pl)
PE (1)	PE20190227A1 (pl)
PH (1)	PH12018502613A1 (pl)
PL (1)	PL3484916T3 (pl)
PT (1)	PT3484916T (pl)
RS (1)	RS61646B1 (pl)
RU (1)	RU2760875C1 (pl)
SG (1)	SG11201811015RA (pl)
SI (1)	SI3484916T1 (pl)
SV (1)	SV2019005807A (pl)
TN (1)	TN2018000419A1 (pl)
TW (1)	TWI747922B (pl)
UA (1)	UA124104C2 (pl)
WO (1)	WO2018011073A1 (pl)
ZA (1)	ZA201808329B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2767532T3 (en)	2012-12-21	2016-09-12	Nat Inst For Quantum And Radiological Science And Tech	New connection for reproduction of tau protein heavy in the brain.
SG10201911349YA (en)	2015-06-05	2020-01-30	Genentech Inc	Anti-tau antibodies and methods of use
JO3711B1 (ar)	2015-07-13	2021-01-31	H Lundbeck As	أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP7029415B2 (ja)	2016-07-12	2022-03-03	ハー・ルンドベック・アクチエゼルスカベット	過リン酸化タウに特異的な抗体およびその使用方法
KR102645073B1 (ko)	2016-12-07	2024-03-11	제넨테크, 인크.	항-타우 항체 및 이의 이용 방법
MA48595A (fr)	2016-12-07	2020-03-18	Ac Immune Sa	Anticorps anti-tau et leurs méthodes d'utilisation
EP3565836A1 (en) *	2017-01-04	2019-11-13	H. Lundbeck A/S	Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
CA3053379A1 (en)	2017-02-17	2018-08-23	Denali Therapeutics Inc.	Anti-tau antibodies and methods of use thereof
TWI809562B (zh)	2017-10-16	2023-07-21	日商衛材R&D企管股份有限公司	抗tau抗體及其用途
JP2021512602A (ja) *	2018-02-01	2021-05-20	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	タウに特異的に結合する結合分子
SG11202008579UA (en) *	2018-03-05	2020-10-29	Janssen Pharmaceutica Nv	Anti-phf-tau antibodies and uses thereof
WO2020123492A1 (en) *	2018-12-10	2020-06-18	New York University	Monoclonal antibodies targeting c-terminal region of phosphorylated tau
JP2022527087A (ja)	2019-03-28	2022-05-30	ハー・ルンドベック・アクチエゼルスカベット	タウオパチーを診断するためのｐＳ３９６アッセイの使用
CN114641490B (zh) *	2019-08-06	2023-06-06	新旭生技股份有限公司	结合至病理性tau种类的抗体及其用途
CN114728071A (zh)	2019-11-13	2022-07-08	新旭生技股份有限公司	用于降解tau蛋白聚集体的化合物及其用途
JPWO2023008415A1 (pl)	2021-07-27	2023-02-02

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en)	1982-06-24	1989-11-23	Japan Chem Res	Long-acting composition
US4681581A (en)	1983-12-05	1987-07-21	Coates Fredrica V	Adjustable size diaper and folding method therefor
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en)	1985-07-05	1988-04-05	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US5776093A (en)	1985-07-05	1998-07-07	Immunomedics, Inc.	Method for imaging and treating organs and tissues
US5101827A (en)	1985-07-05	1992-04-07	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4861581A (en)	1986-12-05	1989-08-29	Cancer Biologics, Inc.	Detection of necrotic malignant tissue and associated therapy
US5750172A (en)	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
US5648471A (en)	1987-12-03	1997-07-15	Centocor, Inc.	One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
DE69032742T2 (de)	1989-08-09	1999-06-17	Rhomed, Inc., Albuquerque, N.Mex.	Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en)	1993-04-26	1994-11-10	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en)	1990-08-29	2005-07-27	GenPharm International, Inc.	Transgenic mice capable of producing heterologous antibodies
LU91067I2 (fr)	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1992022645A1 (en)	1991-06-14	1992-12-23	Genpharm International, Inc.	Transgenic immunodeficient non-human animals
JPH06508880A (ja)	1991-07-08	1994-10-06	ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト	サーモトロピック液晶セグメント化ブロックコポリマー
ATE386115T1 (de)	1991-12-06	2008-03-15	Max Planck Gesellschaft	Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
AU3328493A (en)	1991-12-17	1993-07-19	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
WO1994019935A1 (en)	1993-03-09	1994-09-15	Genzyme Corporation	Isolation of components of interest from milk
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US6077835A (en)	1994-03-23	2000-06-20	Case Western Reserve University	Delivery of compacted nucleic acid to cells
KR970029803A (ko)	1995-11-03	1997-06-26	김광호	반도체 메모리장치의 프리차지 회로
CA2361421A1 (en)	1999-02-03	2000-08-10	Biosante Pharmaceuticals, Inc.	Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en)	1999-05-14	2001-08-28	Copernicus Therapeutics, Inc.	Automated nucleic acid compaction device
IL147765A0 (en)	1999-07-29	2002-08-14	Medarex Inc	HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
AU784012B2 (en)	1999-08-24	2006-01-12	E. R. Squibb & Sons, L.L.C.	Human CTLA-4 antibodies and their uses
US20030162230A1 (en)	2000-09-27	2003-08-28	Reagan Kevin J.	Method for quantifying phosphokinase activity on proteins
AU2002239422B2 (en)	2000-11-30	2006-12-07	E. R. Squibb & Sons, L.L.C.	Transgenic transchromosomal rodents for making human antibodies
AT500379B8 (de) *	2001-02-02	2009-08-15	Axon Neuroscience	Tau-proteine
JP2005538706A (ja)	2001-07-12	2005-12-22	ジェファーソンフーテ，	スーパーヒト化抗体
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US20070134724A1 (en)	2005-08-04	2007-06-14	Peter Davies	Phosphorylation of tau by abl
US10155816B2 (en)	2005-11-28	2018-12-18	Genmab A/S	Recombinant monovalent antibodies and methods for production thereof
EP2185692A4 (en)	2007-08-10	2012-05-02	Medarex Inc	HCO32 AND HCO27 AND RELATED EXAMPLES
EP2185592B1 (en) *	2007-09-13	2013-01-23	University Of Zurich Prorektorat Forschung	Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN102596221B (zh)	2009-06-10	2019-06-04	纽约大学	病理tau蛋白的免疫靶向
EP2625198B1 (en) *	2010-10-07	2015-07-22	AC Immune S.A.	Antibodies recognising phospho-tau
CN103339146B (zh) *	2010-10-11	2017-09-01	比奥根国际神经科学公司	人抗tau抗体
JP6457263B2 (ja) *	2011-05-20	2019-01-23	オリゴメリックスインコーポレイテッド	タウプロテアーゼ組成物および使用方法
CN108034005B (zh) *	2011-10-07	2021-06-25	Ac免疫有限公司	识别Tau的磷酸化特异抗体
JP6293731B2 (ja)	2012-04-05	2018-03-14	エーシーイミューンエス．エー．	ヒト化タウ抗体
WO2014008404A1 (en)	2012-07-03	2014-01-09	Washington University	Antibodies to tau
PL2885010T3 (pl)	2012-08-16	2020-11-16	Ipierian, Inc.	Metody leczenia tauopatii
SG10201707855YA (en)	2013-03-13	2017-10-30	Prothena Biosciences Ltd	Tau immunotherapy
US20160068818A1 (en)	2013-04-16	2016-03-10	Glykos Finland Oy	A method for generating induced pluripotent stem cells
GB201312226D0 (en) *	2013-07-08	2013-08-21	Adx Neurosciences	Improved antibodies
EA033260B1 (ru)	2014-01-23	2019-09-30	Асахи Касеи Кабусики Кайся	Блок-сополимерная композиция и клеевая композиция
JP6913018B2 (ja)	2014-07-08	2021-08-04	ニューヨーク・ユニバーシティ	タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
JO3711B1 (ar) *	2015-07-13	2021-01-31	H Lundbeck As	أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP7029415B2 (ja)	2016-07-12	2022-03-03	ハー・ルンドベック・アクチエゼルスカベット	過リン酸化タウに特異的な抗体およびその使用方法
US10364286B2 (en)	2016-12-22	2019-07-30	H. Lundbeck A/S	Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3565836A1 (en)	2017-01-04	2019-11-13	H. Lundbeck A/S	Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
US10934438B2 (en)	2017-04-27	2021-03-02	Axalta Coating Systems Ip Co., Llc	Coatings and methods for using and producing the same

2017
- 2017-07-07 JP JP2018566490A patent/JP7029415B2/ja active Active
- 2017-07-07 SI SI201730686T patent/SI3484916T1/sl unknown
- 2017-07-07 ES ES17739940T patent/ES2862427T3/es active Active
- 2017-07-07 BR BR112018004916A patent/BR112018004916A2/pt unknown
- 2017-07-07 CA CA3027561A patent/CA3027561A1/en active Pending
- 2017-07-07 SG SG11201811015RA patent/SG11201811015RA/en unknown
- 2017-07-07 CN CN201780036665.XA patent/CN109618556B/zh active Active
- 2017-07-07 RU RU2018143423A patent/RU2760875C1/ru active
- 2017-07-07 MA MA056165A patent/MA56165A/fr unknown
- 2017-07-07 RS RS20210397A patent/RS61646B1/sr unknown
- 2017-07-07 UA UAA201812547A patent/UA124104C2/uk unknown
- 2017-07-07 CN CN202211523102.2A patent/CN116041504A/zh active Pending
- 2017-07-07 KR KR1020197001135A patent/KR102551971B1/ko active IP Right Grant
- 2017-07-07 JO JOP/2018/0117A patent/JOP20180117B1/ar active
- 2017-07-07 PL PL17739940T patent/PL3484916T3/pl unknown
- 2017-07-07 AU AU2017295608A patent/AU2017295608B2/en active Active
- 2017-07-07 MX MX2019000476A patent/MX2019000476A/es unknown
- 2017-07-07 EP EP17739940.9A patent/EP3484916B1/en active Active
- 2017-07-07 MY MYPI2018002441A patent/MY197836A/en unknown
- 2017-07-07 PE PE2018003304A patent/PE20190227A1/es unknown
- 2017-07-07 GE GEAP201714957A patent/GEP20217222B/en unknown
- 2017-07-07 NZ NZ748983A patent/NZ748983A/en unknown
- 2017-07-07 PT PT177399409T patent/PT3484916T/pt unknown
- 2017-07-07 TN TNP/2018/000419A patent/TN2018000419A1/en unknown
- 2017-07-07 EP EP20209554.3A patent/EP3878864A1/en active Pending
- 2017-07-07 WO PCT/EP2017/067067 patent/WO2018011073A1/en unknown
- 2017-07-07 HU HUE17739940A patent/HUE053679T2/hu unknown
- 2017-07-07 LT LTEP17739940.9T patent/LT3484916T/lt unknown
- 2017-07-07 MA MA45655A patent/MA45655B1/fr unknown
- 2017-07-07 DK DK17739940.9T patent/DK3484916T3/da active
- 2017-07-10 TW TW106123060A patent/TWI747922B/zh active
- 2017-07-10 US US15/645,442 patent/US10472415B2/en active Active
2018
- 2018-12-05 IL IL263530A patent/IL263530B2/en unknown
- 2018-12-10 ZA ZA2018/08329A patent/ZA201808329B/en unknown
- 2018-12-11 PH PH12018502613A patent/PH12018502613A1/en unknown
- 2018-12-12 DO DO2018000281A patent/DOP2018000281A/es unknown
- 2018-12-28 CO CONC2018/0014325A patent/CO2018014325A2/es unknown
2019
- 2019-01-07 SV SV2019005807A patent/SV2019005807A/es unknown
- 2019-01-10 CL CL2019000082A patent/CL2019000082A1/es unknown
- 2019-01-11 NI NI201900003A patent/NI201900003A/es unknown
- 2019-01-24 EC ECSENADI20195417A patent/ECSP19005417A/es unknown
- 2019-04-01 US US16/371,902 patent/US10647762B2/en active Active
- 2019-04-01 US US16/371,867 patent/US10487142B2/en active Active
- 2019-09-27 US US16/585,207 patent/US11111290B2/en active Active
2021
- 2021-03-26 CY CY20211100268T patent/CY1123995T1/el unknown
- 2021-03-31 HR HRP20210522TT patent/HRP20210522T1/hr unknown
- 2021-08-11 US US17/399,205 patent/US20220177557A1/en active Pending
- 2021-10-05 JP JP2021164366A patent/JP7244600B2/ja active Active
2024
- 2024-03-05 AU AU2024201450A patent/AU2024201450A1/en active Pending

Also Published As

Publication number	Publication date
IL263530B2 (en)	2023-02-01
AU2024201450A1 (en)	2024-03-28
US20180016330A1 (en)	2018-01-18
DOP2018000281A (es)	2019-02-15
HRP20210522T1 (hr)	2021-05-14
KR20190028436A (ko)	2019-03-18
SV2019005807A (es)	2019-02-13
ECSP19005417A (es)	2019-01-31
JP7244600B2 (ja)	2023-03-22
PE20190227A1 (es)	2019-02-13
AU2017295608B2 (en)	2024-01-04
JP2019529336A (ja)	2019-10-17
MX2019000476A (es)	2019-06-10
EP3484916A1 (en)	2019-05-22
RS61646B1 (sr)	2021-04-29
WO2018011073A1 (en)	2018-01-18
LT3484916T (lt)	2021-04-26
BR112018004916A2 (pt)	2018-12-11
JP7029415B2 (ja)	2022-03-03
CN116041504A (zh)	2023-05-02
MA56165A (fr)	2022-04-20
US20220177557A1 (en)	2022-06-09
CA3027561A1 (en)	2018-01-18
MA45655A (fr)	2019-05-22
SG11201811015RA (en)	2019-01-30
US20190284265A1 (en)	2019-09-19
KR102551971B1 (ko)	2023-07-07
US11111290B2 (en)	2021-09-07
TN2018000419A1 (en)	2020-06-15
TW201809004A (zh)	2018-03-16
US10472415B2 (en)	2019-11-12
MY197836A (en)	2023-07-20
CY1123995T1 (el)	2022-05-27
SI3484916T1 (sl)	2021-08-31
JOP20180117B1 (ar)	2022-03-14
PH12018502613A1 (en)	2019-09-30
EP3484916B1 (en)	2021-03-03
IL263530B (en)	2022-10-01
MA45655B1 (fr)	2021-04-30
US20200109192A1 (en)	2020-04-09
NI201900003A (es)	2020-04-27
US10487142B2 (en)	2019-11-26
GEP20217222B (en)	2021-02-10
US10647762B2 (en)	2020-05-12
US20190284266A1 (en)	2019-09-19
ZA201808329B (en)	2020-02-26
IL263530A (en)	2019-01-31
CO2018014325A2 (es)	2019-01-18
ES2862427T3 (es)	2021-10-07
JOP20180117A1 (ar)	2019-01-30
AU2017295608A1 (en)	2018-12-20
TWI747922B (zh)	2021-12-01
NZ748983A (en)	2022-12-23
CL2019000082A1 (es)	2019-04-05
RU2760875C1 (ru)	2021-12-01
CN109618556A (zh)	2019-04-12
CN109618556B (zh)	2022-10-21
UA124104C2 (uk)	2021-07-21
PT3484916T (pt)	2021-03-31
DK3484916T3 (da)	2021-04-06
HUE053679T2 (hu)	2021-07-28
EP3878864A1 (en)	2021-09-15
JP2022023096A (ja)	2022-02-07

Publication	Publication Date	Title
HK1254357A1 (zh)	2019-07-19	特異性針對過度磷酸化t蛋白的抗體及其使用方法
ZA201808329B (en)	2020-02-26	Antibodies specific for hyperphosphorylated tau and methods of use thereof
IL265800A (en)	2019-06-30	Anti-lag-3 antibodies and methods of using them
SG10201912879YA (en)	2020-02-27	Anti-sirp-alpha antibodies and methods of use thereof
HK1249445A1 (zh)	2018-11-02	抗分揀蛋白抗體和其使用方法
HK1252698A1 (zh)	2019-05-31	抗siglec-9抗體及其使用方法
IL259495A (en)	2018-07-31	Antibodies and methods for using them
SG10201912563XA (en)	2020-02-27	Anti-tim-3 antibodies and methods of use thereof
HK1252696A1 (zh)	2019-05-31	抗siglec-7抗體及其使用方法
EP3515478A4 (en)	2020-07-15	ANTIBODIES FOR SIGLEC-15 AND METHODS OF USING SAME
SG10201912150TA (en)	2020-02-27	Anti-trem2 antibodies and methods of use thereof
ZA202001985B (en)	2022-12-21	Anti-htra1 antibodies and methods of use thereof
IL265957A (en)	2019-05-30	Anti-c1s antibodies and methods of using them
IL267538A (en)	2019-08-29	Antibodies against factor xi and methods of their use